Moderna Stock Price and Forecast: MRNA may fall to $188 or $157


  • Moderna in continuation pattern.
  • Moderna stock has been hammered in November.
  • MRNA shares are down nearly 30% this month.

Moderna (MRNA) stock rallied just over 3% on Wednesday in a continuation of recent small gains seen after the tumultuous hammering the stock has suffered this month. Moderna shares are down 27% over the last month despite recovering somewhat this week, up 6% now. Moderna is still snapping back after stretching too far during the pandemic. The pace of earnings growth has slowed despite the company exploding due to the coronavirus pandemic. Vaccine uptake has likely peaked, and revenue growth slowing will see a reevaluation of the underlying share price. This is what is currently happening. 

Moderna (MRNA) stock news

While many are arguing the development of antiviral pills is what is hurting Moderna's share price the most, we actually feel it was the weak earnings report. This highlighted a few things. Number one: Moderna is way too reliant on one stream of revenue, that of a covid vaccine. It does have numerous other candidates in trial stages, but only a few have reached phase-3 trials. It takes years for treatments to go through stage trials. Covid did see this process speed up, but it will be back to multiple-year development timelines from now on. What the earnings highlighted the most was a revenue growth slowdown. Once that showed up, it was inevitable that investors would reassess and rebalance their Moderna holdings. 

Just in case you are not aware, other headwinds exist. These include the development of antiviral treatments for covid by both Pfizer (PFE) and Merck (MRK) to continuing haggles, which may turn legal, between Moderna and the US government over intellectual property rights for the development of Moderna's covid vaccine. 

Moderna (MRNA) stock forecast

The move remains in our view a consolidation of recent losses. A consolidation means a continuation phase is likely, and so a break lower is the most probable outcome. Only breaking the strong resistance from $255 to $265 will change our view. This is the 200-day moving average and the yearly volume-weighted average price (VWAP), so it is a strong resistance to break above. Instead, we are looking for a break lower to $188.41 and then $157, where it will be time to reevalaute the argument.

MRNA 1-day chart

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.

Feed news

Latest Forex News


Latest Forex News

Editors’ Picks

EUR/USD struggles to rebound, holds near 1.1150 after US data

EUR/USD trades around 1.1150 in the early American session on Friday as investors assess the latest inflation data from the US. According to the US Bureau of Economic Analysis, Core PCE Price Index rose to 4.9% on a yearly basis in December from 4.7% in November, surpassing the market expectation of 4.8%. 

EUR/USD News

GBP/USD clings to small gains above 1.3400 on mixed US data

GBP/USD posts modest daily gains slightly above 1.3400 on Friday as the dollar rally loses steam. The data from the US showed that the core PCE inflation edged higher to 4.9% in December. On a negative note, Personal Spending contracted by 0.6% on a monthly basis.

GBP/USD News

Gold recovers modestly after US data, stays below $1,800

Gold managed to stage a rebound from the multi-week low it set below $1,780 but continues to trade deep in the red near $1,790. The benchmark 10-year US Treasury bond yield is rising more than 1% on the day after US data, limiting XAU/USD's recovery.

Gold News

Bitcoin Weekly Forecast: Federal Reserve cannot tame BTC’s uptrend

Bitcoin has experienced some significant losses over the past few weeks, with a more dramatic drop occurring this week after the Fed's decision was announced. As losses have extended and BTC has entered into the $30,000 zone, concerns regarding Bitcoin being in a bear market have increased.

Read more

Apple share price set to rise after another record quarter

With the Nasdaq closing at its lowest level in seven months yesterday, the Apple share price has also found itself on the end of the recent weakness in tech shares, down over 12% from its record highs in early January.

Read more

Forex MAJORS

Cryptocurrencies

Signatures